Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing SARS-Cov-2 Viral Load.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-14

Study Completion Date

2022-11-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A nasal spray based on Advanced Water S-100 ionized water would clean the nasal cavity, reduce the viscosity of the mucus and facilitate its elimination and the decongestion of the nose and the prevention of the seizure of the SARS-COV-2 to the epithelial cells of the nasal cavity In fact, a nasal spray based on Advanced Water S-100 ionized water would modify the electrostatic environment of all interactions ensuring this seizure. The negative ions (OH-) contained in Advanced Water S-100 compete with the negative ions of the heparan sulfate, which will destabilize this essential bond for the virus to enter the host cell. In addition, positively charged basic amino acids, in the presence of the basic pH of ADW S-100, will be neutralized by OH- ions which will prevent the formation of salt and hydrogen bridges mediating the formation of the protein S/ACE2 complex. The destabilization of all bonds governing the protein S/ACE2 association process will prevent the virus from entering cells and replicating.

The aim of this study is to evaluate whether the use of ADW S-100 ionized water nasal spray reduces the salivary and nasopharyngeal viral load during an 8-day follow-up of persons recently infected with SARS-Cov-2, and thus potentially decreases the risk of contamination of the entourage.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Seawater Nasal Wash to Relieve COVID-19 Nasal Symptoms and Reduce SARS-CoV-2 Viral Load.

NCT04916639

SARS-CoV2 Infection (COVID-19) URTI - Viral Upper Respiratory Tract Infection

COMPLETED NA

Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx

NCT04872686

Virus Infection, RNA Effect of Drug Efficacy, Self

COMPLETED PHASE3

SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial

NCT04802408

Covid19 SARS-CoV Infection

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

NCT04824365

COVID-19

COMPLETED PHASE2/PHASE3

Povidone Iodine Nasal Irrigation and Gargling to Reduce Viral Load in Asymptomatic Patients With COVID-19

NCT05375773

2019 Novel Coronavirus Infection

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, double-blind, placebo-controlled, parallel-group study.

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Advanced Water S-100 ionized nasal spray

2 sprays in each nostril, 6 times a day during 8 days

Group Type EXPERIMENTAL

nasal spray

Intervention Type DEVICE

2 sprays in each nostril, 6 times a day

Nasal spray with purified water

2 sprays in each nostril, 6 times a day during 8 days

Group Type PLACEBO_COMPARATOR

nasal spray

Intervention Type DEVICE

2 sprays in each nostril, 6 times a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nasal spray

2 sprays in each nostril, 6 times a day

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women ≥ 18 years old
2. Informed consent
3. Beneficiaries of a social security plan
4. Vaccinated or unvaccinated against SARS-COV-2:

* Vaccinated individuals have had a 3rd dose for at least one month, or have been infected with SARS-Cov-2 and have had 2 doses of vaccine for at least one month
* Unvaccinated persons are naïve to previous SARS Cov 2 infection
5. Positive nasopharyngeal RT-PCR test for selection with a Ct viral load ≤ 23
6. Have a phone and internet connection to access the entry application

Exclusion Criteria

1. The participant is related to any member of the study staff or has a close relationship or conflict of interest with the sponsor.
2. Known hypersensitivity or allergy to any component of the test product.
3. Contraindication to nasal spray
4. Insufficient vaccination: any incomplete vaccination schedule

* either a 3rd dose within the last month
* or SARS-Cov-2 infection with less than 2 vaccine doses or with 2 vaccine doses less than 1 month old.
5. Any condition, including COVID, that is likely to result in hospitalization during study participation.
6. Conditions that may result in hospitalization during study participation.
7. Known pregnancy or positive urine pregnancy test at D0 by the nurse, or current breastfeeding
8. Participation in an antiviral clinical trial or other trial using a medical device for disease prevention COVID 19

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No